CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2019—SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products. Customers will be able to purchase AccuRef cancer reference materials directly from SeraCare worldwide, with the exception of China, beginning in January.
SeraCare announced in a separate release the commercial launch of an expanded neurotrophic tropomyosin receptor kinase RNA fusion reference material panel developed in a partnership with Bayer. The Seraseq NTRK FFPE RNA reference material contains 15 clinically significant NTRK RNA fusions across NTRK1, NTRK2, and NTRK3 genes and are to be used by clinical laboratories looking to validate their detection by next-generation sequencing methods. The RNA fusions are present inside SeraCare’s reference cell line GM24385 and formalin fixed and paraffin embedded to represent typical processed tumor sections.